Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01270945 | Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis. | PHASE2 | COMPLETED | 43 | — | — | Jun 30, 2011 | Apr 30, 2014 | Mar 30, 2025 | 8 | United States |
adverse events, vitals signs, physical examination results and clinical laboratory values
| Arm | Type | Description |
|---|---|---|
| CV-18C3 and standard of care | EXPERIMENTAL | CV-18C3 and standard of care |
| standard of care | ACTIVE_COMPARATOR | Percutaneous revascularization |
| Name | Type | Description |
|---|---|---|
| CV-18C3 | DRUG | 3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration |
| Standard of Care | PROCEDURE | - |
Inclusion Criteria: * Have suspected superficial femoro-popliteal artery occlusion due to lower extremity pain with exercise or at rest and are undergoing a planned arteriogram. * Subjects will be randomized after angiographic evidence of qualifying lesion Exclusion Criteria: * Acute critical lim...